Simvastatin
-
Subject Areas on Research
- A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
- A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
- Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
- Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes.
- Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome.
- An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.
- Analyses of cancer data from three ezetimibe trials.
- Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.
- Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function.
- Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial.
- Community pharmacists' experience with pharmacogenetic testing.
- Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes.
- Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study.
- Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases.
- Drug therapy increases bone density in osteonecrosis of the femoral head in canines.
- Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
- Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial.
- Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.
- Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
- Effect of simvastatin on retinal vascular caliber: the Age-Related Maculopathy Statin Study.
- Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).
- Effects of simvastatin on retinal structure and function of a high-fat atherogenic mouse model of thickened Bruch's membrane.
- Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.
- Enteric microbiome metabolites correlate with response to simvastatin treatment.
- Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
- Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model.
- Expression quantitative trait locus analysis identifies novel genes for statin myopathy.
- Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial.
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
- Ezetimibe plus a Statin after Acute Coronary Syndromes.
- Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
- Galbraith Award: simvastatin attenuates experimental cerebral vasospasm and ameliorates serum markers of neuronal and endothelial injury in patients after subarachnoid hemorrhage: a dose-response effect dependent on endothelial nitric oxide synthase.
- HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
- Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms.
- Improvement in the function of hibernating myocardium in a patient with heart failure due to coronary artery disease receiving high-dose simvastatin.
- Learning to walk before we run: the mechanics of medical intervention for peripheral arterial disease.
- Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
- Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.
- Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
- Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment.
- On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).
- Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients.
- Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
- Overcoming inertia: improvement in achieving target low-density lipoprotein cholesterol.
- Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
- Premature release of data from clinical trials of ezetimibe.
- Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
- Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
- Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
- Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.
- Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful?
- Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
- RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.
- Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury.
- Simvastatin in subarachnoid haemorrhage: beyond the short-term.
- Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage.
- Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial.
- Simvastatin suppresses cyclophosphamide-induced changes in urodynamics and bladder inflammation.
- Simvastatin treatment duration and cognitive preservation in experimental subarachnoid hemorrhage.
- Simvastatin treatment improves functional recovery after experimental spinal cord injury by upregulating the expression of BDNF and GDNF.
- Statin-associated memory loss: analysis of 60 case reports and review of the literature.
- Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION.
- Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach.
- Statins inhibit toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression.
- Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments.
- Synthes Award for Resident Research in Spinal Cord & Spinal Column Injury: Statins for the treatment of neurological injury: a role beyond cholesterol lowering.
- The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy.
- The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
- The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial.
- The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
- The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
- The influence of statin medications on prostate-specific antigen levels.
-
Keywords of People
- Laskowitz, Daniel Todd, Professor of Neurology, Duke Innovation & Entrepreneurship
- Warner, David Samuel, Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology